Clinical course and outcomes in adults with co-occurring hypertrophic cardiomyopathy and hypertension: a scoping review protocol

Milla Arabadjian; Barnaby Nicolas; Sophie Montgomery; Mitchell Pleasure; Maxine Collins; Maria Reuter; Daniele Massera; Daichi Shimbo; Mark Sherrid

doi:10.1136/bmjopen-2023-075087

Clinical course and outcomes in adults with co-occurring hypertrophic cardiomyopathy and hypertension: a scoping review protocol

BMJ Open. 2023 Jul 18;13(7):e075087. doi: 10.1136/bmjopen-2023-075087.

Authors

Milla Arabadjian¹, Barnaby Nicolas², Sophie Montgomery³, Mitchell Pleasure³, Maxine Collins⁴, Maria Reuter⁵, Daniele Massera⁵, Daichi Shimbo⁶, Mark Sherrid⁵

Affiliations

¹ Center for Population and Health Services Research, Department of Foundations of Medicine, NYU Long Island School of Medicine, Mineola, New York, USA milla.arabadjian@nyulangone.org.
² Department of Foundations of Medicine, NYU Long Island School of Medicine, Mineola, New York, USA.
³ NYU Grossman School of Medicine, New York City, New York, USA.
⁴ University of Connecticut School of Nursing, Storrs, Connecticut, USA.
⁵ Hypertrophic Cardiomyopathy Program, Leon H. Charney Division of Cardiology, Department of Medicine, NYU Langone Health, New York City, New York, USA.
⁶ Division of Cardiology, Department of Medicine, Columbia University Irving Medical Center, New York City, New York, USA.

Abstract

Introduction: Hypertension affects 40%-60% of adults with hypertrophic cardiomyopathy (HCM), the most common inherited cardiac condition. It can be a diagnostic confounder for HCM, contributing to delayed diagnosis. Clinically, treatment of co-occurring hypertension and HCM poses challenges as first-line and second-line antihypertensive medications are often contraindicated in HCM. The clinical course in adults with hypertension and HCM is also not well understood, and studies examining patient outcomes in this population are equivocal. In this paper, we aim to outline the protocol of a scoping review, a type of literature review, to systematically synthesise existing knowledge on adults with co-occurring HCM and hypertension, highlighting knowledge and evidence gaps, and identifying future research directions to optimise outcomes in this population.

Methods and analysis: This review is guided by Arksey and O'Malley's conceptual framework on conducting scoping reviews. We will search five electronic databases (PubMed, CINAHL, Scopus, Embase and Web of Science) and reference lists of publications to identify eligible articles focusing on medical therapy, clinical course or outcomes in adults with HCM and hypertension, between 2011 and 2023. Our search strategy and presentation of results will be guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses-Scoping Review guideline. First, two independent reviewers will screen articles, by title and abstract, followed by a full-text screen to identify eligible articles. Relevant data will be extracted and synthesised.

Ethics and dissemination: Ethical approval is not required for this review as it is a secondary data collection of published articles and does not involve human subject participation. We will present results of this review at relevant professional conferences and patient-centred educational events. Results will be published in a peer-reviewed journal.

Trial registration number: https://osf.io/cy8qb/?view_only=98197f4850584e51807ff9b62533a706.

Keywords: cardiology; hypertension; hypertrophic cardiomyopathy.

Publication types

Review

MeSH terms

Adult
Cardiomyopathy, Hypertrophic* / complications
Cardiomyopathy, Hypertrophic* / therapy
Disease Progression
Humans
Hypertension* / complications
Hypertension* / drug therapy
Research Design
Review Literature as Topic
Systematic Reviews as Topic